Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Provides Business Update

Receives positive feedback from FDA on pivotal study protocol for Anaphylm™ (epinephrine) Sublingual FilmReaffirms fourth quarter 2023 Anaphylm pivotal Phase 3 study start and first quarter 2024...
September 20, 2023 09:04 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film

WARREN, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care...
September 11, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date

FDA Acceptance of Libervant™ (diazepam) Buccal Film NDA for treatment of seizure clusters in patients between two and five years of agePrescription Drug User Fee Act (PDUFA) target goal date set for...
August 23, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

WARREN, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...
August 07, 2023 16:01 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Submitted proposed pivotal trial protocol for Anaphylm™ (epinephrine) Sublingual Film to the FDASubmitted an NDA to the FDA for Libervant™ (diazepam) Buccal Film for patients between two and five...
August 02, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference

WARREN, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...
July 27, 2023 07:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film

Reports positive topline data from latest pilot pharmacokinetic (PK) studyPlans to submit pivotal PK clinical study protocol to the FDA in early AugustAnticipates commencement of its definitive...
July 25, 2023 16:01 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET

WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...
July 25, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference

WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...
July 06, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit

WARREN, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...